Share
Summarize with AI
Key takeaways
Regulatory Status: Not FDA-approved for human use. As of September 2023, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the FD&C Act, meaning it is prohibited from use in compounded medications for human administration. Ipamorelin has never received FDA approval for any indication. Research Stage: Preclinical data available; one failed Phase 2 RCT (postoperative ileus, 2014). No completed human efficacy trials for GH-related indications. Availability: Not legally marketed for human use in the United States. Superpower Health does not offer this substance. Prescribing information: View compound reference data (PubChem CID 20515892) What it is: A synthetic pentapeptide that selectively activates the growth hormone secretagogue receptor (GHS-R1a) to stimulate pulsatile GH release. What the evidence actually shows: Selective GH stimulation without cortisol or prolactin elevation in animal models; its sole human RCT failed to meet its primary endpoint.
Where ipamorelin comes from and how it works
Origin and discovery
Ipamorelin (also referred to by its Novo Nordisk research designation NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s. It emerged from a medicinal chemistry program aimed at identifying orally active or injectable growth hormone secretagogues with an improved selectivity profile compared to earlier compounds in the class.
Raun, Hansen, and colleagues, publishing in a 1998 paper in the European Journal of Endocrinology, first described ipamorelin as "the first selective growth hormone secretagogue" — a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that released GH in conscious swine with an ED50 of 2.3 ± 0.03 nmol/kg and an Emax of 65 ± 0.2 ng/mL plasma, at potency comparable to GHRP-6 but without the ACTH, cortisol, FSH, LH, prolactin, or TSH elevations seen with earlier GHRPs even at doses 200-fold above the GH-release ED50.
The companion medicinal chemistry paper by Ankersen and colleagues in the Journal of Medicinal Chemistry that year detailed the SAR program and the new series of highly potent GH-releasing peptides derived from the ipamorelin scaffold. A 1999 paper by Hansen and colleagues in the European Journal of Endocrinology later characterized NN703, a subsequent orally active GH secretagogue from the same Novo Nordisk program. The compound does not occur naturally in the body; it is an entirely synthetic molecule.
The ghrelin receptor and GHS-R1a agonism
Ipamorelin works by binding to and activating the growth hormone secretagogue receptor subtype 1a, designated GHS-R1a. This receptor is the same receptor that ghrelin, the endogenous hunger and GH-releasing hormone, activates. In 1999, Kojima and colleagues identified ghrelin in a landmark paper in Nature, establishing it as the endogenous ligand for GHS-R1a.
A 2005 review by Kojima and Kangawa in Physiological Reviews, a 2015 review by Müller and colleagues in Molecular Metabolism, and a 2020 review by Abizaid and Hougland in Trends in Endocrinology and Metabolism together provide comprehensive coverage of ghrelin receptor biology and its signaling complexity. An earlier 1998 review by Bowers in Cellular and Molecular Life Sciences remains an authoritative reference for the GHS class as a whole.
Ipamorelin mimics this interaction: by binding GHS-R1a on somatotroph cells in the anterior pituitary, it triggers the release of growth hormone in a pulsatile pattern that preserves the hypothalamic feedback mechanisms governing GH secretion. This is mechanistically distinct from GHRH analogs such as sermorelin, which activate a separate receptor on the same cells. The two receptor pathways are complementary, which is why ipamorelin is sometimes studied alongside GHRH analogs; the combination article addresses that context separately.
The selectivity story: What makes ipamorelin different
Most growth hormone secretagogues developed before ipamorelin stimulated GH but also produced secondary hormonal effects. Arvat, di Vito, and colleagues in a 1997 study in Peptides administered GHRP-2 and hexarelin (1 μg/kg IV) to young healthy adults and showed that both peptides produced GH responses greater than GHRH along with slight but real stimulation of prolactin, ACTH, and cortisol — with ACTH/cortisol-releasing activity similar in magnitude to that of human CRH — establishing that earlier-generation GHRPs are not hormonally "clean."
The mechanism involves off-target activation of non-GHS-R1a pathways, including CRF (corticotropin-releasing factor) pathways. Ipamorelin's published pharmacological profile is substantially different. The 1998 paper demonstrated that equimolar doses of ipamorelin stimulated GH release in pigs at levels comparable to GHRP-6 while producing no statistically significant elevation in ACTH or cortisol. Prolactin was similarly unaffected. This three-way selectivity, GH stimulation without cortisol, prolactin, or ACTH elevation, established ipamorelin as the benchmark for GHS selectivity in the academic literature and drove its adoption in compounded practice before regulatory classification changed.
Pharmacokinetics: Half-life and the pulsatility question
Ipamorelin is a peptide and is therefore rapidly cleared from circulation. Gobburu and colleagues in a 1999 PK/PD modeling study in Pharmaceutical Research characterized ipamorelin behavior in human volunteers and reported a short half-life of approximately two hours. This rapid clearance is relevant to how the compound was used in compounded practice, typically via subcutaneous injection timed to align with the natural nocturnal GH pulse, but it also means the window of receptor activation is brief.
The pulsatile GH release pattern generated by GHS-R1a agonism more closely resembles physiological secretion than continuous delivery of exogenous HGH, which suppresses endogenous pituitary output entirely.
Malmlöf and colleagues in a 1999 paper in Growth Hormone and IGF Research also demonstrated in rats that methylprednisolone (5.0 mg/kg for 8 days) did not blunt the acute plasma GH response to either ipamorelin or GHRH, and that repeated IV ipamorelin dosing (0.4 or 1.6 mg/kg/day × 10 days) in glucocorticoid-treated rats raised IGF-1 and significantly reduced methylprednisolone-induced weight loss (P < 0.05) — supporting that the GH-IGF-1 axis remains responsive to GHS stimulation during glucocorticoid exposure.
What the human evidence looks like
The only completed human RCT
As of April 2026, one completed, peer-reviewed randomized controlled trial of ipamorelin in humans has been published. Beck, Sweeney, and McCarter, publishing a proof-of-concept Phase 2 RCT in the International Journal of Colorectal Disease in 2014, investigated of ipamorelin for postoperative ileus following bowel resection. The trial was not an investigation of ipamorelin's growth-hormone-related effects; it tested whether the compound's gastroprokinetic properties could accelerate gastrointestinal recovery after bowel surgery.
The study enrolled 117 patients (114 composed the safety and modified intent-to-treat populations) and randomized them to IV ipamorelin 0.03 mg/kg twice daily versus placebo for up to 7 days or hospital discharge, with median time to first tolerated meal as a key efficacy measure. The ipamorelin arm showed a numerical but non-significant improvement (25.3 vs. 32.6 hours, p = 0.15), no significant differences were seen on the key and secondary efficacy analyses, and the regimen was well tolerated.
Ipamorelin did not meet its efficacy endpoints, and clinical development in this indication was discontinued. Preclinical gastrointestinal motility data from Venkova and colleagues in a 2009 study in the Journal of Pharmacology and Experimental Therapeutics and Greenwood-Van Meerveld and colleagues in a 2012 study in the Journal of Experimental Pharmacology had supported the rodent hypothesis; the human data did not replicate it.
GH-related effects: Animal data and the evidence gap
The GH-releasing properties of ipamorelin, which drove its widespread use in compounded practice, have been studied in animals but not in completed human efficacy trials. Johansen and colleagues, publishing in a 1999 paper in Growth Hormone and IGF Research, demonstrated that ipamorelin induced statistically significant longitudinal bone growth in hypophysectomized rats. Svensson and colleagues published a 2000 study in the Journal of Endocrinology showing that ipamorelin and GHRP-6 both increased bone mineral content in adult female rats.
Lall and colleagues reported in a 2001 paper in Biochemical and Biophysical Research Communications that GH secretagogues, including ipamorelin, stimulated adiposity-related changes in rodents through a GH-independent pathway. Jiménez-Reina, Cañete, and colleagues, in a 2002 study in Histology and Histopathology, treated young female rats with ipamorelin, GHRH, or saline for 21 days and reported that chronic ipamorelin exposure did not alter somatotroph ultrastructure but increased the volume density of secretion granules, consistent with sustained pituitary secretory activity without evident somatotroph exhaustion in this rodent model.
All of these endpoints are preclinical. There are no completed human trials examining ipamorelin's effects on body composition, lean mass, bone density, recovery, or IGF-1 in humans for these indications.
Why ipamorelin became the dominant GHS in compounded practice
Despite the absence of human efficacy data for GH-related endpoints, ipamorelin became the most commonly prescribed growth hormone secretagogue in US compounding practice in the years before the 2023 FDA action. Two factors drove this. First, its selectivity profile, established in the 1998 Raun paper, was accurately communicated in clinical circles as a meaningful pharmacological advantage over GHRP-2, GHRP-6, and hexarelin.
Second, the IGF-1 monitoring data available from the literature, including a 2017 retrospective study by Sigalos, Pastuszak, and colleagues in the American Journal of Men's Health — 14 men on testosterone therapy treated with a GHRP-6 / GHRP-2 / SERM stack, with mean IGF-1 rising from 159.5 to 239.0 ng/mL (p < 0.0001) — provided a measurable biomarker endpoint that providers could track, although the small retrospective design limits the strength of inference.
That combination, a clean selectivity story and a trackable biomarker, created a compelling clinical rationale even in the absence of Phase 3 efficacy data. The 2023 FDA Category 2 classification ended legal access through compounding.
Regulatory and legal status
FDA classification
As of April 2026, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the Federal Food, Drug, and Cosmetic Act. This classification, which the FDA finalized in September 2023, places ipamorelin on the list of substances that may not be used in compounded drug preparations for human administration under the 503A compounding framework. Category 2 does not mean the substance is inherently dangerous; it means the FDA determined the substance lacks sufficient evidence to support a finding that the benefit-risk profile justifies inclusion on the list of bulk substances that may be compounded. Ipamorelin has never received FDA approval as a drug for any human therapeutic indication. The reference source for the 503A bulk drug substances process is the FDA's current 503A bulk drug substances list.
Sport ban status
For athletes, there is a separate regulatory consideration. As of the 2026 WADA Prohibited List, ipamorelin is prohibited under category S2 (peptide hormones, growth factors, related substances, and mimetics). This classification applies both in- and out-of-competition. Detection methodology for ipamorelin metabolites in urine following nasal or injectable administration was characterized by Semenistaya, Zvereva, and colleagues in a 2015 study in Drug Testing and Analysis, meaning ipamorelin is detectable through established anti-doping testing. A 2012 review in Endocrine Reviews by Baumann provides authoritative context on GH doping detection strategies across this class. Competitive athletes subject to WADA or USADA jurisdiction who use ipamorelin risk disqualification.
What this means practically
With that regulatory context established, ipamorelin is not legally obtainable in pharmaceutical-grade form for human use in the United States. Products labeled as ipamorelin sold through online vendors, research chemical suppliers, or gray-market peptide sources are not FDA-regulated. They are manufactured without pharmaceutical oversight and have not been tested for purity, sterility, or accurate dosing. Independent testing of peptide research products has repeatedly found contamination, incorrect concentrations, and misidentified compounds. There is no legal compounding pathway for ipamorelin under current 503A rules, and Superpower does not offer ipamorelin in any form.
Ipamorelin vs. related growth hormone secretagogues: Key differences
Ipamorelin belongs to the GHS-R1a agonist class, which it shares with GHRP-2, GHRP-6, and hexarelin. It also operates in the same physiological context as GHRH analogs such as sermorelin and tesamorelin, though through an entirely different receptor pathway. Understanding these distinctions requires attention to both receptor biology and the evidence base for each compound.
The pharmacological distinction between ipamorelin and GHRP-2, GHRP-6, and hexarelin centers on selectivity. All four compounds activate GHS-R1a and stimulate GH release. GHRP-2 and hexarelin, however, also activate non-GHS-R1a pathways that drive ACTH and cortisol secretion. The 1997 Arvat paper establishing this in humans remains the primary reference. Ipamorelin does not produce these secondary hormonal effects at equivalent doses, according to the 1998 Raun selectivity data. This selectivity profile was the scientific basis for preferring ipamorelin in clinical practice, and it distinguishes ipamorelin from hexarelin, which also carries evidence of cardiac effects not seen with ipamorelin. It should be noted that GHRP-2, GHRP-6, and hexarelin are themselves not available through legal compounding channels and are not eligible for content on this platform.
The distinction between ipamorelin and GHRH analogs such as sermorelin involves a different comparison. Sermorelin activates the GHRH receptor on pituitary somatotrophs; ipamorelin activates GHS-R1a. These receptors are different proteins that initiate overlapping but distinct intracellular signaling cascades. Both ultimately result in GH release, but the regulatory inputs differ. Sermorelin's mechanism is subject to negative feedback via somatostatin; GHS-R1a agonism has a partially somatostatin-independent mechanism, which is why the two receptor pathways have been described as complementary in the preclinical literature. This comparison is provided for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases, and the comparison does not constitute a clinical recommendation.
Safety: What is and is not known
Absence of clinical safety data for GH-related uses
The only published human safety data for ipamorelin comes from the 2014 Beck postoperative ileus RCT and the 1999 Gobburu pharmacokinetic study in volunteers. Neither evaluated the safety profile associated with long-term subcutaneous administration for GH-related purposes. There are no Phase 1 or Phase 2 safety studies of ipamorelin for body composition, bone density, or recovery endpoints in humans. The absence of this data means that claims about ipamorelin's safety profile in the context of long-term use are not supported by clinical evidence.
The 2018 class review by Sigalos and Pastuszak in Sexual Medicine Reviews characterized the available safety evidence for GH secretagogues as limited and noted that most data derive from short-duration studies.
A more recent 2023 review by Smith and Thorner in the Journals of Gerontology Series A revisited the rationale for GHSs as potential therapeutics to restore GH secretion in older adults to young-adult levels, and a 2020 review by Sinha and colleagues in Translational Andrology and Urology addressed GHS use in body composition management in hypogonadal males — while cataloguing the evidence gap.
Risks from unregulated sources
Because ipamorelin has no legal compounding pathway in the United States, any product currently available for purchase is sourced from unregulated suppliers. Peptide products sold as research chemicals or through online vendors are not subject to FDA manufacturing standards. Contamination with endotoxins, incorrect peptide sequences, degraded material, and unknown impurities have been documented in independent analyses of gray-market peptide products. The 2012 Endocrine Reviews paper on GH doping in sport by Baumann noted the quality control challenges specific to this category. Dosing inconsistency is a practical safety concern even in the absence of an inherent toxicological hazard from the compound itself.
Who should use ipamorelin
The short answer: no one, outside an IRB-approved clinical research study. Ipamorelin is classified as an FDA 503A Category 2 bulk drug substance, prohibited for use in compounded medications for human administration. It has no FDA-approved indication, and its only completed Phase 2 human trial failed to meet its primary endpoint. There is no US population for whom use of this compound is supported by evidence.
Several mechanistic considerations amplify that default position. These are illustrative, not a contraindication checklist — there is no approved indication:
Active or suspected malignancy — GH and IGF-1 stimulation are growth-promoting signals; the theoretical concern that GHS-R1a agonism could support tumor proliferation or angiogenesis is unresolved Acromegaly or elevated baseline IGF-1 — additional receptor-mediated stimulation could compound existing risks Type 2 diabetes or impaired glucose tolerance — GH has insulin-antagonist effects; GH secretagogues carry a theoretical risk of worsening insulin resistance Competitive athletes subject to anti-doping rules — ipamorelin is prohibited under the 2026 WADA Prohibited List (S2 category) Pregnancy or breastfeeding — no reproductive or developmental toxicology data in humans Hypothyroidism or other pituitary axis disorders — GH secretagogue responses may be attenuated or unpredictable
Which biomarkers are relevant if you are exploring growth hormone science?
Understanding your baseline GH axis and metabolic markers provides meaningful context regardless of which interventions you are evaluating. These markers directly reflect the physiological pathways ipamorelin engages.
IGF-1 (insulin-like growth factor 1): The primary downstream biomarker for GH axis activity. GH stimulates IGF-1 production primarily in the liver; circulating IGF-1 reflects integrated GH secretion over the preceding hours. Because GH itself has a short half-life and is released in pulses, IGF-1 is the practical clinical surrogate for GH axis function and the most relevant monitoring marker for any GHS intervention. The 2017 Sigalos and colleagues study specifically used serum IGF-1 as the primary efficacy biomarker in their GHS assessment. Understanding your baseline IGF-1 also matters in the context of the relationship between IGF-1 and longevity, where both deficiency and excess carry distinct risk profiles. Fasting glucose and insulin: GH has counter-regulatory effects on insulin, and GH secretagogue use carries a theoretical risk of impairing glucose homeostasis. Baseline fasting glucose and insulin quantify metabolic starting point and help identify individuals in whom GH axis stimulation would require closer monitoring. Cortisol: Ipamorelin's selectivity claim specifically concerns its lack of cortisol elevation versus GHRP-2, GHRP-6, and hexarelin. Measuring baseline cortisol provides a reference point relevant to understanding the compound's purported selectivity advantage and whether other variables (sleep, stress, hypothalamic function) are affecting the HPA axis independently. Comprehensive metabolic panel: Liver and kidney function testing establishes organ health baseline. The liver is the primary site of IGF-1 synthesis. Abnormal hepatic function can distort IGF-1 levels and confound interpretation of any GH axis intervention. Complete blood count: A general safety baseline. While ipamorelin does not have a known direct hematological effect, comprehensive baseline testing before evaluating any investigational compound is standard clinical practice. Body composition markers (where available): Because GH axis stimulation is studied for effects on lean mass and adipose tissue, having a quantified baseline for body composition biomarkers makes any changes in that domain interpretable over time.
When to take this seriously
If the symptoms that drive interest in growth hormone secretagogues, fatigue, poor recovery, changes in body composition, or disrupted sleep, are persistent and affecting quality of life, those are real concerns with established clinical pathways. A primary care physician, endocrinologist, or sports medicine provider can assess GH axis function through established diagnostic protocols. Understanding baseline IGF-1, glucose metabolism, thyroid function, and metabolic health through bloodwork provides the objective data that makes any clinical conversation productive. Starting with clear biomarker data gives any subsequent evaluation something concrete to work from.
That principle, test first so that decisions are grounded in data rather than symptoms alone, reflects Superpower's approach to preventive health: the conviction that understanding your biology is a precondition for every meaningful health decision, whether that involves established therapies or navigating emerging research.
IMPORTANT SAFETY INFORMATION
Ipamorelin is not FDA-approved for any indication and has never completed the Phase 3 clinical trials required for FDA drug approval. As of September 2023, ipamorelin is classified as a Category 2 bulk drug substance under Section 503A of the FD&C Act, prohibiting its use in compounded medications for human administration. Superpower Health does not prescribe, sell, compound, or facilitate access to ipamorelin in any form.
There are no FDA-approved prescribing guidelines or established safety parameters for ipamorelin use in humans for growth hormone-related indications. The absence of completed Phase 1 safety trials for these indications means the human side effect profile, contraindication profile, and drug interaction profile are not established by clinical data.
Ipamorelin should not be used by anyone outside an IRB-approved clinical research study; there is no approved indication and no contraindication table because there is no approved use. Populations of particular theoretical concern based on proposed mechanism include: active or suspected malignancy (GH and IGF-1 stimulation may support tumor growth); acromegaly or elevated baseline IGF-1; type 2 diabetes or impaired glucose tolerance (GH has insulin-antagonist effects); pregnancy or breastfeeding (no safety data); known hypopituitary disorders requiring supervised GH management.
Warnings: Products sold online as ipamorelin are not FDA-regulated, lack pharmaceutical-grade purity standards, and may contain contaminants, incorrect concentrations, or misidentified compounds. Competitive athletes: ipamorelin is prohibited under the 2026 WADA Prohibited List (S2 category) both in- and out-of-competition. Long-term safety data in humans does not exist for GH-secretagogue indications.
As of April 2026, no compounding pharmacy may legally prepare ipamorelin for human use under Section 503A. Any ipamorelin product available for purchase in the United States falls outside the regulated pharmaceutical supply chain.
FAQs
No. Ipamorelin has never been FDA-approved for any human therapeutic indication. Its only completed human RCT, a Phase 2 trial for postoperative ileus published by Beck and colleagues in 2014, failed to meet its primary endpoint, and Novo Nordisk discontinued clinical development. Ipamorelin has not undergone the Phase 3 trials required for FDA approval.
As of April 2026, ipamorelin is classified as a Category 2 bulk drug substance under FDA Section 503A rules, meaning it cannot be legally used in compounded medications for human administration. This classification was finalized in September 2023. Products sold online as ipamorelin are not regulated and do not have a legal pathway to human use in the United States.
No licensed provider can legally prescribe ipamorelin in the United States under current regulations. The Category 2 classification prohibits its inclusion in any compounded preparation for human use. There is no FDA-approved manufactured form of ipamorelin to prescribe. Any product available online falls outside the regulated pharmaceutical supply chain.
The FDA's Section 503A bulk drug substance review process evaluates whether specific compounds may be used in compounded medications. Ipamorelin was placed in Category 2 in September 2023, meaning the FDA determined there was insufficient evidence to support its continued use in compounding. This removed the legal pathway that had allowed compounding pharmacies to prepare and dispense ipamorelin under physician prescription. The February 2026 reclassification of additional peptides affected compounds such as BPC-157 and other substances but did not change ipamorelin's Category 2 status, which had already been established.
Ipamorelin is a GHS-R1a agonist that mimics ghrelin's receptor. Sermorelin is a GHRH analog that activates the GHRH receptor. Both ultimately stimulate GH release from the pituitary, but through different receptor pathways with different regulatory inputs. Sermorelin's mechanism is subject to somatostatin-mediated suppression; ipamorelin's GHS-R1a pathway is partially independent of somatostatin regulation. As of April 2026, sermorelin is not FDA-approved for adult use but retains a different regulatory classification than ipamorelin.
The primary distinction is hormonal selectivity. Ipamorelin, as Raun and colleagues established in 1998, stimulates GH without producing significant elevations in ACTH, cortisol, or prolactin. GHRP-2 and hexarelin activate non-GHS-R1a pathways that elevate cortisol and ACTH alongside GH release, as documented by Arvat and colleagues in 1997. GHRP-6 also lacks ipamorelin's selectivity, with additional effects on appetite mediated by ghrelin pathway activation. GHRP-2, GHRP-6, and hexarelin are themselves Category 2 or otherwise ineligible for compounding and are not offered by Superpower.
References
PubChem (National Library of Medicine). (n.d.). Tert-butyl 8-methyl-9-oxo-2,4,8,11-tetrazatricyclo[8.4.0.02,6]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate. https://pubchem.ncbi.nlm.nih.gov/compound/20515892 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552-61. https://doi.org/10.1530/eje.0.1390552 Ankersen, M., Johansen, N. L., Madsen, K., Hansen, B. S., Raun, K., Nielsen, K. K., Thogersen, H., Hansen, T. K., Peschke, B., Lau, J., Lundt, B. F., & Andersen, P. H. (1998). A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of medicinal chemistry, 41(19), 3699-704. https://doi.org/10.1021/jm9801962 Hansen, B. S., Raun, K., Nielsen, K. K., Johansen, P. B., Hansen, T. K., Peschke, B., Lau, J., Andersen, P. H., & Ankersen, M. (1999). Pharmacological characterisation of a new oral GH secretagogue, NN703. European journal of endocrinology, 141(2), 180-9. https://doi.org/10.1530/eje.0.1410180 Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-60. https://doi.org/10.1038/45230 Kojima, M., & Kangawa, K. (2005). Ghrelin: structure and function. Physiological reviews, 85(2), 495-522. https://doi.org/10.1152/physrev.00012.2004 Müller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., Casanueva, F. F., D'Alessio, D., Depoortere, I., Geliebter, A., Ghigo, E., Cole, P. A., Cowley, M., Cummings, D. E., Dagher, A., ... Tschöp, M. H. (2015). Ghrelin. Molecular metabolism, 4(6), 437-60. https://doi.org/10.1016/j.molmet.2015.03.005 Abizaid, A., & Hougland, J. L. (2020). Ghrelin Signaling: GOAT and GHS-R1a Take a LEAP in Complexity. Trends in endocrinology and metabolism: TEM, 31(2), 107-117. https://doi.org/10.1016/j.tem.2019.09.006 Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and molecular life sciences : CMLS, 54(12), 1316-29. https://doi.org/10.1007/s000180050257 Arvat, E., di Vito, L., Maccagno, B., Broglio, F., Boghen, M. F., Deghenghi, R., Camanni, F., & Ghigo, E. (1997). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides, 18(6), 885-91. https://doi.org/10.1016/s0196-9781(97)00016-8 Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 16(9), 1412-6. https://doi.org/10.1023/a:1018955126402 Malmlöf, K., Johansen, P. B., Haahr, P. M., Wilken, M., & Oxlund, H. (1999). Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 9(6), 445-50. https://doi.org/10.1054/ghir.1999.0128 Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 29(12), 1527-34. https://doi.org/10.1007/s00384-014-2030-8 Venkova, K., Mann, W., Nelson, R., & Greenwood-Van Meerveld, B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 329(3), 1110-6. https://doi.org/10.1124/jpet.108.149211 Greenwood-Van Meerveld, B., Tyler, K., Mohammadi, E., & Pietra, C. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 4, 149-55. https://doi.org/10.2147/JEP.S35396 Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 9(2), 106-13. https://doi.org/10.1054/ghir.1999.9998 Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., & Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology, 165(3), 569-77. https://doi.org/10.1677/joe.0.1650569 Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132-8. https://doi.org/10.1006/bbrc.2000.4065 Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707-14. https://doi.org/10.14670/HH-17.707 Sigalos, J. T., Pastuszak, A. W., Allison, A., Ohlander, S. J., Herati, A., Lindgren, M. C., & Lipshultz, L. I. (2017). Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American journal of men's health, 11(6), 1752-1757. https://doi.org/10.1177/1557988317718662 U.S. Food and Drug Administration. (n.d.). Bulk drug substances nominated use compounding under section 503a fdc act. https://fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdc-act World Anti-Doping Agency. (n.d.). The Prohibited List. https://wada-ama.org/en/prohibited-list Semenistaya, E., Zvereva, I., Thomas, A., Thevis, M., Krotov, G., & Rodchenkov, G. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug testing and analysis, 7(10), 919-25. https://doi.org/10.1002/dta.1787 Baumann, G. P. (2012). Growth hormone doping in sports: a critical review of use and detection strategies. Endocrine reviews, 33(2), 155-86. https://doi.org/10.1210/er.2011-1035 Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45-53. https://doi.org/10.1016/j.sxmr.2017.02.004 Smith, R. G., & Thorner, M. O. (2023). Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults. The journals of gerontology. Series A, Biological sciences and medical sciences, 78(Suppl 1), 38-43. https://doi.org/10.1093/gerona/glad022 Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149-S159. https://doi.org/10.21037/tau.2019.11.30
You should also read
Betaine HCL: Who Needs It for Low Stomach Acid
Rucking: Calorie Burn, Joint Impact, and Who It's Good For
William Maish, MD MBA MPH
Cortisol Face: What's Real and How to Test Your Own
William Maish, MD MBA MPH
PCOS and Belly Weight: The Hormones Behind It
William Maish, MD MBA MPH
Creatine Gummies vs. Powder: Which Form Actually Works?
William Maish, MD MBA MPH
Apple Cider Vinegar Gummies: Worth It or Just Hype?
William Maish, MD MBA MPH
Beef Tallow for Skin: Hype or Legitimate Remedy?
William Maish, MD MBA MPH
Mugwort Tea: What It Does and Who Should Avoid It
William Maish, MD MBA MPH
Does Okra Water Actually Do Anything?
William Maish, MD MBA MPH
Mushroom Coffee: Does It Actually Do Anything?
William Maish, MD MBA MPH
Red Light Therapy Panels: Which Wavelengths Actually Do Something
William Maish, MD MBA MPH
GABA for Sleep: The Blood-Brain Barrier Problem Nobody Mentions
William Maish, MD MBA MPH
Triphala: The Evidence Behind Ayurveda's Most Famous Formula
William Maish, MD MBA MPH
Sleepmaxxing: Which Practices Have Evidence Behind Them
William Maish, MD MBA MPH
Sleep Divorce: When Sleeping Apart Is Good for Your Health
William Maish, MD MBA MPH
Postbiotics: The Part of Gut Health Nobody Talks About
William Maish, MD MBA MPH
Oral Hyaluronic Acid: Does It Actually Improve Joints and Skin?
William Maish, MD MBA MPH
Zone 2 Running: How to Know You're Actually Training in Zone 2
William Maish, MD MBA MPH
Infrared Sauna Blankets vs. Regular Saunas: Are They Worth It?
William Maish, MD MBA MPH
NSDR: What Non-Sleep Deep Rest Does to Your Brain
William Maish, MD MBA MPH
Do Acupressure Mats Relieve Pain or Improve Sleep?
William Maish, MD MBA MPH
Does the Sleepy Girl Mocktail Help You Sleep?
William Maish, MD MBA MPH
Greens Powder: What You're Getting (and What It Can't Replace)
William Maish, MD MBA MPH
Probiotic Soda: Do the Bacteria Survive to Your Gut?
William Maish, MD MBA MPH
Emu Oil for Skin: What It Does and What It Doesn't
William Maish, MD MBA MPH
Ash Gourd Juice: Traditional Claims vs. What Science Shows
William Maish, MD MBA MPH
Psyllium Husk Capsules vs. Powder: Which Form Works Better?
William Maish, MD MBA MPH
Does Topical Magnesium Spray Absorb Through Skin?
William Maish, MD MBA MPH
What Somatic Exercises Do to Your Nervous System
William Maish, MD MBA MPH
Castor Oil Packs: What They Do and What They Don't
William Maish, MD MBA MPH
Raspberry Leaf Tea in Pregnancy: What the Evidence Says
William Maish, MD MBA MPH
NMN Supplements: What They Do to NAD+ (and Whether It Matters)
William Maish, MD MBA MPH
What Is the Winter Arc and Does It Hold Up?
William Maish, MD MBA MPH
Liquid Chlorophyll: What the Evidence Shows and What's Marketing
William Maish, MD MBA MPH
75 Soft vs. 75 Hard: Which Challenge Is Worth It?
William Maish, MD MBA MPH
Dihydroberberine vs. Berberine: Is the Upgrade Worth the Price?
William Maish, MD MBA MPH
Does Chromium Picolinate Reduce Cravings and Blood Sugar?
William Maish, MD MBA MPH
Weighted Vests: The Science Behind Bone Density and Calorie Burn
William Maish, MD MBA MPH
Nano Hydroxyapatite Toothpaste: Is It Better Than Fluoride?
William Maish, MD MBA MPH
Sea Moss Gel: What It Contains (and the Thyroid Risk)
William Maish, MD MBA MPH
Does Prebiotic Soda Actually Reach Your Gut?
William Maish, MD MBA MPH
Under-Desk Treadmills: How Much Walking at Work Changes Your Health
William Maish, MD MBA MPH
The Glucose Goddess Method: Which Hacks Hold Up to Science
William Maish, MD MBA MPH
Walking Pads: How Many Steps Actually Move the Needle?
William Maish, MD MBA MPH
Ox Bile Supplements: Who Needs Them After Gallbladder Removal
William Maish, MD MBA MPH
The Animal-Based Diet: What It Is and What the Research Shows
William Maish, MD MBA MPH
The Low Histamine Diet: Who Needs It and How to Know
William Maish, MD MBA MPH
Berberine Phytosome: More Effective Than Regular Berberine?
William Maish, MD MBA MPH
PEMF Mats: What They Do and When They Work
William Maish, MD MBA MPH
What Is Hurkle Durkle — and Is Lying in Bed Good for You?
William Maish, MD MBA MPH
Redmond Real Salt: Does the Mineral Content Actually Matter?
William Maish, MD MBA MPH
Why Brown Noise Helps You Focus (and Sleep)
William Maish, MD MBA MPH
The Carnivore Diet: What Happens to Your Body After 30 Days
William Maish, MD MBA MPH
Magnesium L-Threonate: Does It Actually Cross the Blood-Brain Barrier?
William Maish, MD MBA MPH
Perifit Pelvic Floor Trainer: How It Works and Who Benefits
William Maish, MD MBA MPH
Benfotiamine vs. Regular B1: What's Different and When to Use It
William Maish, MD MBA MPH
Kefir Grains vs. Store-Bought Kefir: What's Different Probiotic-Wise?
William Maish, MD MBA MPH
Mouth Taping for Sleep: Who Should Try It and Who Should Skip It
William Maish, MD MBA MPH
Does Castor Oil Make Your Eyelashes Grow?
William Maish, MD MBA MPH
Celtic Sea Salt: Is It Worth Switching From Regular Salt?
William Maish, MD MBA MPH
Tart Cherry Juice: The Research on Sleep, Recovery, and Uric Acid
William Maish, MD MBA MPH
Blue Lotus Tea: What It Does to Your Brain and Whether It's Legal
William Maish, MD MBA MPH
Slippery Elm: What It Does in the Gut and What the Evidence Shows
William Maish, MD MBA MPH
Ceylon Cinnamon vs. Cassia: Why the Difference Matters
William Maish, MD MBA MPH
Seed Cycling for Hormones: What the Science Shows
William Maish, MD MBA MPH
Does Dry Brushing Move Lymph or Improve Skin?
William Maish, MD MBA MPH
Monk Mode: Does the Productivity Research Actually Back It Up?
William Maish, MD MBA MPH
The Raw Carrot Salad: What Ray Peat's Theory Gets Right and Wrong
William Maish, MD MBA MPH
Lion's Mane Powder vs. Capsules: Which Form Works Best?
William Maish, MD MBA MPH
Dopamine Detox: What Neuroscience Says (and What Actually Helps)
William Maish, MD MBA MPH
The Low Oxalate Diet: Who Needs It and Why
William Maish, MD MBA MPH
DIM Supplements: What the Estrogen-Metabolism Evidence Actually Shows
William Maish, MD MBA MPH
What 'California Sober' Means — and the Health Trade-Offs
William Maish, MD MBA MPH
Chia Seed Water: Does It Help Weight Loss, Satiety, or Blood Sugar?
William Maish, MD MBA MPH
Nasal Dilators: Internal vs. External — Which Works Better?
William Maish, MD MBA MPH
Do Nasal Strips Reduce Snoring or Help Athletic Performance?
William Maish, MD MBA MPH
The Adrenal Cocktail: What Each Ingredient Actually Does
William Maish, MD MBA MPH
Urolithin A: The Mitophagy Compound Your Gut May Not Be Making
William Maish, MD MBA MPH
The Dopamine Menu: A Smarter Alternative to Detoxing
William Maish, MD MBA MPH
Apigenin for Sleep: What This Chamomile Compound Does
William Maish, MD MBA MPH
Butyrate Supplements: Worth Taking or Just Feed Your Gut?
William Maish, MD MBA MPH
Do Compression Boots Speed Up Recovery?
William Maish, MD MBA MPH
Shatavari: Evidence for Menopause, Lactation, and Female Health
William Maish, MD MBA MPH
Inulin Powder: Prebiotic Benefits, Gas Risk, and the Right Dose
William Maish, MD MBA MPH
Cycle Syncing: What Your Hormones Do Each Phase of the Month
William Maish, MD MBA MPH
Oatzempic: What It Is and Why It's Nothing Like Ozempic
William Maish, MD MBA MPH
Total T4: The Thyroxine Pool Your Binding Proteins Can Inflate
William Maish, MD MBA MPH
Glycation Gap: When Your HbA1c and Glucose Disagree
William Maish, MD MBA MPH
eGFR (Estimated Glomerular Filtration Rate): Your Kidneys' Filtration Speedometer
William Maish, MD MBA MPH
Fructosamine: A Two-to-Three-Week Window on Your Blood Sugar
William Maish, MD MBA MPH
Ferritin-to-Albumin Ratio (FAR): What a High Score Says About Inflammation
William Maish, MD MBA MPH
Vitamin C, Decoded: Why the Sample Matters as Much as the Result
William Maish, MD MBA MPH
TPO Antibodies: The Thyroid Signal That Shows Up Years Early
William Maish, MD MBA MPH
Free Androgen Index (FAI): The Bioavailable Testosterone Your Total Count Hides
William Maish, MD MBA MPH
Ferritin: The Iron Marker That Drops Before Anemia Shows
William Maish, MD MBA MPH
hCG: Fertility, Testosterone Support, and How This Glycoprotein Hormone Works
William Maish, MD MBA MPH
Tretinoin: A Prescription Retinoid for Acne, Photoaging, and Hyperpigmentation
William Maish, MD MBA MPH
Metformin: An Insulin Sensitizer Used for Blood Sugar and Longevity Research
William Maish, MD MBA MPH
Enclomiphene: A Selective Estrogen Receptor Modulator for Testosterone Support
William Maish, MD MBA MPH
Low-Dose Naltrexone: An Off-Label Approach to Immune Modulation and Chronic Pain
William Maish, MD MBA MPH
Built by the world’s top doctors and scientists
Dr Anant Vinjamoori, MD
Chief Longevity Officer, Superpower
Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in WSJ, Forbes, and Fortune.
Learn more
Dr Leigh Erin Connealy, MD
Clinician & Founder of The Centre for New Medicine
Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.
Learn more
Dr Robert Lufkin
UCLA Medical Professor, NYT Bestselling Author
A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.
Learn more
Dr Abe Malkin
Founder & Medical Director of Concierge MD
Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company
Learn more
Medical Advisory Board
Medical Advisory Board
1 / 3
Your membership starts here
Annual 100+ biomarker panel
Data dashboard and digital twin
Upload past labs and connect wearables
Personalized health protocol
24/7 care team access
AI companion for all health questions
Marketplace with additional solutions
$199
/year*
Billed annually
HSA/ FSA eligible
Cancel anytime
Results in a week
* Pricing may vary for members in New York and New Jersey